


Program	Indications	Pre-Clinical	Phase 1	Phase 1b	Phase 2
FPA008 CSF-1R antibody 	Multiple tumor settings in combination with <i>Opdivo</i> [®] Pigmented Villonodular Synovitis (PVNS)				
FPA144 FGFR2b antibody	Gastric Cancer				
FP-1039 FGF ligand trap	Mesothelioma				
Preclinical Candidates	Multiple Cancers				